Efficacy of Optimal dose of Regional Citrate Anticoagulation versus salineflushing in preventing blood circuit clot for intermittent hemodialysis ; A Prospective Randomized Clinical Trial

Phase 3

• Conditions: hypocalcemiahypernatremia metabolic alkalosiscardiac arrhythmia; Regional citrate anticoagulants; Saline flushing; intermittent hemodialysis

• Registration Number: TCTR20210421004
• Lead Sponsor: Bhumibol Adulyadej Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-21
• Study Completion: 2021-05-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Acute setting ; AKI,ESRD
Age > 18 yrs
Informed consent
Undergoing central venous catheters or AVF/AVG, by prescription HD: Low flux dialyzer
BFR 200 ml/min
Dialyzate Ca 1.75 mEq/L
Duration 4 hr

Exclusion Criteria

1.Patients were treated withantiplatelet,oral anticoagulant therapyorotherdrugs known to affect coagulation within 7 days
2. Acute liver failure
3. DIC
4. Contraindication to systemicanticoagulation:
Abnormal plasmatotal calcium <7.0 mg/dL
Abnormal plasmatotal magnesium <1.8 mg/dL
Abnormal plasmatotal sodium >145 mg/dL
metabolic alkalosis; serum bicarb > 28 mEq/L
Known allergy to citrate
Documented arrhythmia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dialyzer clots 0,30,60,120,180,240 min percent of dialyzer clots

Secondary Outcome Measures

Name	Time	Method
hypocalcemia 0,30,60,120,180,240 min incidence of hypocalcemia ,hypernatremia 0,30,60,120,180,240 min incidence of hypernatremia ,Metabolic alkalosis 0,30,60,120,180,240 min incidence of metabolic alkalosis ,cardiac arrhythmia 0,30,60,120,180,240 min incidence of cardiac arrhythmia ,Saline group 0,30,60,120,180,240 min dialyzer clot incidence